MK-7762 (TBD09)

Synonym(s): MK7762  |  MK 7762  |  TBD 09  |  TBD-09

Class: Oxazolidinone

Details of activity:	Active against Mycobacterium tuberculosis; protein synthesis inhibitor (targets 50S ribosomal subunit)
Description:	Synthetic compound
Institute where first reported:	Bill & Melinda Gates Medical Research Institute; Merck
Year first mentioned:	2023
Highest developmental phase:	Phase 1 (NCT05824091)
Development status:	Active (as of 2024)

Chemical structure(s):
Canonical SMILES:	COC(=O)NC[C@H]1CN(C2=CC(=C(C(=C2)F)N3CCS(=O)(=O)CC3)F)C(=O)O1
Isomeric SMILES:	COC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2)F)N3CCS(=O)(=O)CC3)F
InChI:	InChI=1S/C16H19F2N3O6S/c1-26-15(22)19-8-11-9-21(16(23)27-11)10-6-12(17)14(13(18)7-10)20-2-4-28(24,25)5-3-20/h6-7,11H,2-5,8-9H2,1H3,(H,19,22)/t11-/m0/s1
InChI Key:	CCYKSCLMFZLAJH-NSHDSACASA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/156857753

External links:
Main Source:	https://www.newtbdrugs.org/pipeline/compound/tbd09-mk7762